Synlogic, Inc. (NASDAQ:SYBX) Short Interest Up 42.9% in December

Synlogic, Inc. (NASDAQ:SYBX) saw a significant growth in short interest in December. As of December 15th, there was short interest totalling 88,300 shares, a growth of 42.9% from the November 30th total of 61,800 shares. Based on an average daily trading volume, of 30,200 shares, the short-interest ratio is presently 2.9 days. Approximately 1.3% of the shares of the stock are sold short.

Synlogic Stock Down 3.6 %

Shares of SYBX stock traded down $0.05 during trading hours on Friday, hitting $1.36. 72,705 shares of the company’s stock traded hands, compared to its average volume of 51,174. The stock has a market cap of $15.91 million, a PE ratio of -0.33 and a beta of 0.83. The stock’s 50 day simple moving average is $1.42 and its 200 day simple moving average is $1.48. Synlogic has a 12 month low of $1.22 and a 12 month high of $5.12.

Synlogic (NASDAQ:SYBX) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.17. Synlogic had a negative return on equity of 207.84% and a negative net margin of 2,284.65%. As a group, equities research analysts expect that Synlogic will post -2.71 EPS for the current fiscal year.

Synlogic Company Profile

Synlogic, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.